Meta-analysis of 13,243 patients links GLP-1 drugs to less papilledema in intracranial hypertension

A new systematic review and meta-analysis published in the journal Headache found that GLP-1 receptor agonists were associated with a lower risk of papilledema, a type of optic nerve swelling caused by high pressure inside the skull, in people with idiopathic intracranial hypertension (IIH) ^[1]. The analysis pooled data from eight studies covering 13,243 patients and searched PubMed, Embase, Web of Science, and the Cochrane Library through December 2025 ^[1].

IIH is a condition in which pressure builds up around the brain for no clear cause, often causing headaches and vision problems, and it disproportionately affects women with obesity ^[1]. Because GLP-1 drugs such as semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) can produce substantial weight loss, researchers have been studying whether they might also ease the pressure problems seen in IIH ^[1].

The pooled results showed papilledema risk was lower at three months, with a risk ratio of 0.430, meaning the swelling was seen less often in patients on GLP-1 drugs compared with those who were not ^[1]. At 24 months, the risk ratio was 0.469, suggesting the lower rate of papilledema persisted over roughly two years ^[1]. The three-month finding came with notable variation across studies, reflected in an I-squared statistic of 62.5%, a measure of how much the individual study results differed from one another ^[1].

Headache frequency was also lower among patients taking GLP-1 drugs, with risk ratios of 0.690 and 0.796 reported for this outcome, according to the summary of findings ^[1]. The review additionally reported fewer visual disturbances and less refractory IIH, meaning fewer cases where the disease resisted standard treatment, in the GLP-1 group ^[1].

Despite these associations, the study's authors were careful to flag major limitations. Most of the underlying evidence came from observational studies rather than randomized trials, and the authors judged this evidence to carry a moderate to serious risk of confounding, the statistical problem where some other factor, such as differences in weight loss or diabetes status between groups, could explain the results instead of the drug itself ^[1]. Risk of bias was assessed using two standard tools, one for nonrandomized studies and one for randomized trials, and the authors concluded that the overall certainty of the evidence was low ^[1]. They wrote that the findings are useful mainly for guiding the design of future randomized controlled trials rather than for changing clinical practice today ^[1].

Why it matters for patients

For people living with IIH, this analysis raises the possibility that GLP-1 drugs could someday play a role in managing the condition alongside existing treatments. But because the evidence comes mostly from observational data with a real risk of confounding, patients should understand that the connection between these drugs and reduced papilledema is not yet proven cause and effect ^[1]. IIH treatment decisions currently rest on established options, and this study does not establish GLP-1 drugs as a treatment for the condition ^[1]. The low certainty rating means more rigorous research is needed before firm conclusions can be drawn about who might benefit and how much ^[1].

What happens next

The study's authors called for randomized controlled trials to test GLP-1 receptor agonists specifically in IIH populations, describing the current pooled findings as a foundation for designing such trials rather than a final answer ^[1]. No specific trial timelines were given in the available materials. The paper was accompanied by a companion commentary in the same issue of Headache discussing how GLP-1 drugs may reshape thinking about IIH, though details of that discussion were not included in the material reviewed here ^[1].